Baseline characteristics

Antineoplaston Therapy in Treating Patients With Brain Tumors · Source last updated 2017-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      40

   units

   Participants

groups

1. description

   Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).

   id

   BG000

   title

   Antineoplaston Therapy

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            18.1

            upper Limit

            64.2

            value

            36.0

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            18

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            22

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice